Pharmaceutical Executive spoke with Aradigm Health CEO Will Shrank at the Asembia ASX26 Summit in Las Vegas. During the conversation, he explained the issues the payers face with cell & gene therapies ...
Ultimately, making RWE actionable means shortening the gap between insight and application. When data is reliable, complete, and easy to use, it can support better decisions, faster adoption of new ...
FDA authorization supports a mid-stage clinical evaluation of CK0802 in steroid-refractory GVHD, where steroid nonresponse is ...
In today's Pharmaceutical Executive Daily, Cellenkos announces FDA clearance of its investigational new drug application for ...
UCB enters agreement to acquire Candid Therapeutics in a deal worth up to $2.2 billion, adding BCMA-targeting T-cell engager ...
BioNTech reports its first quarter finical results, including losses and declining Covid-19 revenue as the company ...
Aradigm Health CEO Will Shrank discusses the shift in value-based care models for cell and gene therapies. While advances in ...
In today's Pharmaceutical Executive Daily, UCB announces a definitive agreement to acquire Candid Therapeutics for up to $2.2 ...
Integrated operating frameworks are displacing fragmented vendor ecosystems, enabling faster launch readiness, omnichannel ...
DTP functions as an “affordability waterfall,” dynamically routing patients to MFN cash pricing, commercial insurance, or ...
Pharmaceutical Executive spoke with Aradigm Health CEO Will Shrank at the Asembia ASX26 Summit in Las Vegas. During the ...
FDA cleared the first agent with an NMDA/sigma-1–based mechanism specifically for agitation in Alzheimer’s disease dementia, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results